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TARGET GROUP
Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD).
TECHNOLOGY DESCRIPTION
Nintedanib (Ofev; BIBF 1120) is a small molecule tyrosine kinase inhibitor (TKI) developed for the treatment of idiopathic pulmonary fibrosis (IPF). SSc-ILD and IPF share similarities in terms of the formation of lung scarring, or fibrosis. 1 SSc-ILD is a pulmonary fibrosing disorder characterised by systemic inflammation and progressive scarring of the lungs that leads to respiratory failure. 2 Nintedanib targets growth factor receptors, which have been shown to be involved in the mechanisms by which pulmonary fibrosis occurs. Most importantly, nintedanib inhibits platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR). By blocking the signalling pathways that are involved in fibrotic processes, it is believed that nintedanib has the potential to reduce disease progression in lungs diseases such as IPF by slowing the decline of lung function. 3 In the phase III clinical trial (NCT02597933), nintedanib is given as 150 mg capsules twice daily over 52 weeks up to a maximum of 100 weeks in people with in people with SSc-ILD. 4, 5 Nintedanib is also in phase III development for the treatment of Mesothelioma 6, 7 and Progressive fibrosing ILD (PF-ILD). 8, 9 Nintedanib (Ofev) is licensed in the EU for the treatment of adults with idiopathic pulmonary fibrosis (IPF). The most common side effects with Nintedanib (Ofev) (which may affect more than 1 in 10 people) are diarrhoea, nausea, abdominal pain and raised levels of liver enzymes in the blood. Vomiting, decreased appetite and weight loss are also common.
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INNOVATION and/or ADVANTAGES
Nintedanib is approved for the treatment of IPF, which is a rare lung disease, and has been shown to slow disease progression as measured by annual rate of decline in lung function. Because SSc-ILD and IPF share similarities in how the underlying lung scarring, or fibrosis, forms in people with the disease, nintedanib is being evaluated if it can have a beneficial impact on lung fibrosis associated with SSc. This may address the unmet needs of people affected by rare diseases and serious respiratory conditions, including fibrotic lung diseases.
1 Therefore, if licensed, nintedanib may offer an additional treatment option (the first licensed) for patients with SSc-ILD.
DEVELOPER
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AVAILABILITY, LAUNCH or MARKETING
Nintedanib was granted Orphan Drug Designation for IPF and SSc in the EU in 2013 and 2016 respectively.
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Nintedanib is a designated orphan drug in USA for the treatment of SSc (including the associated interstitial lung disease) in 2016, mesothelioma 2016, and for the treatment of patients with idiopathic pulmonary fibrosis in 2011. 12 
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PATIENT GROUP
BACKGROUND
Systemic Sclerosis (SSc or Scleroderma) is an uncommon condition that results in hard, thickened areas of skin and sometimes problems with internal organs and blood vessels. SSc is caused by the immune system attacking the connective tissue under the skin and around internal organs and blood vessels. This causes scarring and thickening of the tissue in these areas. There are two main types of scleroderma, namely; localised scleroderma, which just affects the skin; and systemic sclerosis, which may affect blood circulation and internal organs as well as the skin.
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SSc can affect the joints, muscles, blood vessels and digestive system. It affects the lungs in about half the people with the condition.
14 It can also affect the kidneys and heart. 14, 15 Systemic sclerosis develops because of changes that occur in the body's connective tissues. It leads to too much fibrous connective tissue, which is similar to scars that form after an injury. Scar tissue contains a protein called collagen. Having too much collagen can cause the body's tissues to stiffen and thicken. The exact reason of why this happens is not yet known. The immune system appears to be overactive and attacks healthy body tissues instead. This leads to cells in the connective tissue producing too much collagen, causing scarring and thickening (fibrosis) of the tissue. This is thought to be due to a mix of genetic and environmental factors. Having a close family member with the condition may increase the risk of developing the condition. However, systemic sclerosis isn't passed directly from one generation to another nor it is contagious. 14 Symptoms of SSc include increased sensitivity to the cold, changes in the skin, pain or stiffness in the joints or muscles, and digestive problems. Inflammation and scarring of the lung tissue is called interstitial lung disease or ILD.
13,14,16 ILD is a common pulmonary manifestation among patients with SSc. The pathogenesis of SSc-ILD is not well understood. It is presumed to be related to abnormal interactions between endothelial cells, lymphocytes/monocytes and fibroblasts leading to an excess production of extracellular matrix by fibroblasts in the setting of tissue hypoxia and vascular hyperreactivity. 17 In many, the ILD develops very early and very rapidly but once established can be very stable for years. In others, the ILD continues to damage the lung on an on-going basis. This situation is critically important to recognise since prevention of lung injury becomes the essential issue in treatment. 16 The most common presenting symptom of ILD is dyspnoea on exertion. Other indicators of ILD may include non-productive cough, fatigue and chest pain. The most common finding on physical examination is the presence of dry (velcro-like) crackles at the lung bases. However, some patients with SSc-ILD may not have any symptoms, and physical exam may be normal. Therefore, the clinician must remain ever vigilant, screening all patients initially and monitoring them frequently throughout the course of their disease. Changes in pulmonary function can occur before the onset of significant clinical symptoms. Therefore, it is important that all patients have screening pulmonary function tests (PFTs) at the time of presentation.
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Involvement of the lungs causes shortness of breath or fatigue during physical activity. Many patients with SSc become less physically active because of musculoskeletal complaints or the fatiguing nature of the illness. Lungs involvement in all its forms in patients with SSc has emerged to be the leading cause of death and disability.
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CLINICAL NEED and BURDEN OF DISEASE
Because of the rarity and heterogeneous clinical presentation of SSc, reliable epidemiological studies on this condition have been particularly difficult to carry out. 19 The first epidemiological study of scleroderma in the UK, a population based study, was conducted in the West Midlands Region. This study suggests prevalence rates of 13 and 48 per million in males and females respectively, with annual incidence rates of 1 and 6 per million. 20 The annual incidence rate of SSc in England was reported to be 3.7 per million in 1986. The worldwide prevalence of SSc is reported to vary from 3 -24 per 100,000. The condition is more common in North America and Australia than in Europe. Women are affected more often than men, and those of African origin are also more affected. The peak age of onset is 40-50 years but it can affect any age group. It is rare in children. 19, 21 It is estimated that SSc-ILD affects up to 200,000 people in Europe, making it an orphan, or rare disease. 22 A retrospective study in the UK assessed the mortality rate and predictors of mortality in a cohort of 204 patients with SSc who enrolled onto the Royal National Hospital for Rheumatic Diseases Connective Tissue Disease database between 1999 and 2010. The overall Standardised Mortality Rate (SMR) was 1.34 (95% confidence interval 1.00-1.75). The SMR was higher in males. The most common cause of SSc-related mortality was pulmonary complications. ILD was among the factors that were found to adversely affect survival.
NHS
Digital, Hospital Episode Statistics for England 2016-17 shows that there were 3,654 hospital admissions for SSc (ICD 10 code: M34), 3,842 Finished Consultant Episodes
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PATIENT PATHWAY RELEVANT GUIDANCE NICE GUIDANCE
 NICE technology appraisal in development. Idiopathic pulmonary fibrosis -pirfenidone (review TA282) (ID837). Expected date of issue to be confirmed.  NICE technology appraisal. Nintedanib for treating idiopathic pulmonary fibrosis (TA379). January 2016  NICE technology appraisal. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282). April 2013  NICE clinical guideline. Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163). June 2013 (updated: May 2017).  NICE quality standard. Idiopathic pulmonary fibrosis in adults (QS79). January 2015. 
NHS ENGLAND and POLICY GUIDANCE

CURRENT TREATMENT OPTIONS
Patients with advanced SSc-ILD need to be treated, and patients with earlier disease should also have therapeutic intervention, especially when there is a high risk of disease progression. 25 There is currently no licensed therapy for SSc-ILD and few drugs have been assessed in clinical trials for this disease. 1 Treatment approaches of SSc-ILD include:  Lung transplantation: this should be considered for patients who progress to end-stage lung disease despite medical treatment, however, transplant centres have been reluctant to consider SSc-ILD patients given the high prevalence of gastroesophageal reflux and its attendant risks for aspiration, bronchiolitis obliterans and allograft rejection. 
ESTIMATED COST and IMPACT
COST
Nintedanib (Ofev®) is already marketed in the UK for the treatment of IPF. 27 The company has agreed a patient access scheme with the Department of Health. 
